| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/21/2022 | 25% | JP Morgan | → $17 | Initiates Coverage On | → Neutral |
| 09/19/2022 | 76.47% | Wedbush | → $24 | Initiates Coverage On | → Outperform |
| 08/18/2022 | 32.35% | Barclays | $12 → $18 | Maintains | Overweight |
| 08/10/2022 | 32.35% | Raymond James | $14 → $18 | Maintains | Outperform |
| 07/14/2022 | 2.94% | Raymond James | $10 → $14 | Maintains | Outperform |
| 05/11/2022 | 10.29% | SVB Leerink | $16 → $15 | Maintains | Outperform |
| 04/26/2022 | -11.76% | Barclays | $18 → $12 | Maintains | Overweight |
| 04/26/2022 | -26.47% | Raymond James | $19 → $10 | Maintains | Outperform |
| 04/18/2022 | 39.71% | Raymond James | → $19 | Initiates Coverage On | → Outperform |
| 04/06/2022 | 39.71% | UBS | → $19 | Initiates Coverage On | → Buy |
| 11/09/2021 | 17.65% | SVB Leerink | $15 → $16 | Maintains | Outperform |
| 08/10/2021 | 10.29% | SVB Leerink | $19 → $15 | Maintains | Outperform |
| 03/24/2021 | 83.82% | HC Wainwright & Co. | $24 → $25 | Reiterates | → Buy |
| 10/19/2020 | 10.29% | HC Wainwright & Co. | $31 → $15 | Maintains | Buy |
| 10/14/2020 | 47.06% | Cantor Fitzgerald | $33 → $20 | Maintains | Overweight |
| 10/13/2020 | 113.24% | SVB Leerink | $36 → $29 | Maintains | Outperform |
| 07/14/2020 | 142.65% | Cantor Fitzgerald | $25 → $33 | Reiterates | → Overweight |
| 06/29/2020 | 127.94% | HC Wainwright & Co. | → $31 | Initiates Coverage On | → Buy |
| 05/20/2020 | 164.71% | SVB Leerink | $27 → $36 | Reiterates | → Outperform |
| 04/22/2020 | 120.59% | Piper Sandler | → $30 | Initiates Coverage On | → Overweight |
| 02/27/2020 | 54.41% | Barclays | → $21 | Initiates Coverage On | → Overweight |
| 12/17/2019 | 83.82% | Cantor Fitzgerald | $34 → $25 | Reiterates | → Overweight |
| 12/06/2019 | 150% | Cantor Fitzgerald | → $34 | Initiates Coverage On | → Overweight |
| 12/03/2019 | 135.29% | B of A Securities | → $32 | Reinstates | → Buy |
| 10/30/2019 | 127.94% | Berenberg | → $31 | Initiates Coverage On | → Buy |
| 03/05/2019 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
| 03/05/2019 | — | SVB Leerink | Initiates Coverage On | → Outperform | |
| 03/05/2019 | 98.53% | Barclays | → $27 | Initiates Coverage On | → Overweight |
| 03/05/2019 | — | B of A Securities | Initiates Coverage On | → Buy |
Gossamer Bio Questions & Answers
The latest price target for Gossamer Bio (NASDAQ: GOSS) was reported by JP Morgan on September 21, 2022. The analyst firm set a price target for $17.00 expecting GOSS to rise to within 12 months (a possible 25.00% upside). 11 analyst firms have reported ratings in the last year.
The latest analyst rating for Gossamer Bio (NASDAQ: GOSS) was provided by JP Morgan, and Gossamer Bio initiated their neutral rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Gossamer Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Gossamer Bio was filed on September 21, 2022 so you should expect the next rating to be made available sometime around September 21, 2023.
While ratings are subjective and will change, the latest Gossamer Bio (GOSS) rating was a initiated with a price target of $0.00 to $17.00. The current price Gossamer Bio (GOSS) is trading at is $13.60, which is within the analyst's predicted range.